Skip to main content
Premium Trial:

Request an Annual Quote

Varian: Phil Febbo

Varian has appointed Phil Febbo to its board of directors. Febbo currently serves as chief medical officer at Illumina as well as on the board of the American College of Medical Genetics and Genomics Foundation. Prior to joining Illumina, he served as CMO at Genomic Health. Before working at Genomic Health, Febbo was a professor of medicine and urology at the University of California, San Francisco. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.